
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis is a biopharmaceutical company with a strong presence in the oncology market through its two FDA-approved drugs – Cabometyx and Cotellic – for the treatment of various cancers. The company has consistently exceeded revenue and earnings expectations, driven by solid demand and market share growth for Cabometyx. Exelixis has also been actively repurchasing its stock, indicating confidence in its financial strength and growth prospects. With promising results from ongoing clinical trials and a solid pipeline, Exelixis is well-positioned for future growth and potential acquisitions.
Bears say
Exelixis is facing several challenges that may impact its financial performance, including competition from other drug companies, potential clinical development failures, and pricing and reimbursement changes. While there are opportunities for growth with the development of new products and potential success in clinical trials, there are also significant risks that could prevent the company from achieving its financial forecasts. Additionally, the company's valuation, based on a discounted cash flow analysis, suggests a price target of $54 per share, but this could change depending on the success and challenges faced by the company in the future.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares